|
|
|
Calcitonin
(CT) - Elisa
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reagents |
96
tests Kit |
Color Code |
Reconstitution |
|
Microtiterplate
with 96 anti CT (monoclonal antibodies) coated wells |
96
wells |
blue |
Ready
for use |
|
|
1.2
ml |
|
Dilute
11 x with conjugate buffer |
|
|
1
vial 11
ml |
red |
Ready
for use |
|
(see
exact values on vial labels) in CT-Free human serum |
6
vials lyophil. |
yellow |
Add
0.5 ml distilled water |
|
|
1
vial lyophil. |
black |
Add
buffer (see reconstitution volume on the label) |
|
|
1
vial 8
ml |
black |
Ready
for use |
|
|
1
vial 10
ml |
brown |
Dilute
200 x with distilled water (use a magnetic stirrer). |
|
in
human serum with gentamycin |
2
vials lyophil. |
silver |
Add
0.5 ml distilled water |
|
|
1
vial 25
ml |
white |
Ready
for use |
|
|
1
vial 25
ml |
white |
Ready
for use |
Note:
1.
CT
free human serum is to be used for samples dilution.
2. 1 pg of our reference
preparation is equivalent to 0.19 μIU
MRC 89/620.
5
SUPPLIES NOT PROVIDED
The
following material is required but not provided in the kit:
1.
High quality distilled water
2.
Pipettes for delivery of: 50 μl, 100 μl, 200 µl, 500 µl and 1
ml (the use of accurate pipettes with disposable plastic tips is recommended)
3.
Vortex mixer
4.
Magnetic stirrer
5.
Horizontal microtiterplate shaker capable of 700 rpm ± 100 rpm
6.
Washer for microtiterplates
7.
Microtiterplate reader capable of reading at 450 nm, 490 nm and 650 nm
(in case of polychromatic reading) or capable of reading at 450 nm and 650 nm
(monochromatic reading)
8.
Optional equipment: The ELISA-AID™ necessary to read the plate
according to polychromatic reading (see paragraph XI.A.) can be purchased from
Robert Maciels Associates, Inc. Mass. 0.2174 USA.
6
REAGENT PREPARATION
a.
Calibrators
: Reconstitute the calibrators with 0.5 ml distilled water.
b.
Controls
: Reconstitute the controls with 0.5 ml distilled water.
c.
Working Wash solution
: Prepare an adequate volume of Working Wash solution by adding 199 volumes of
distilled water to 1 volume of Wash Solution (200x). Use a magnetic stirrer to
homogenize. Discard unused Working Wash solution at the end of the day.
d.
CT Free Serum:
Reconstitute the CT Free Serum with the amount of Buffer as indicated on the
vial label. Allow it to remain
undisturbed until completely dissolved, then mix well by gentle inversion.
e.
Working anti-CT-HRP
conjugate: Following the
number of wells to be used, dilute the concentrated conjugate (11x) with the
conjugate buffer in a clear glass vial according to the table below.
Extemporaneous dilution is recommended.
|
Number
of wells |
Concentrated
conjugate (11x) (ml) |
Conjugate
Buffer (ml) |
Working
Volume (ml) |
|
8 16 24 32 48 96 |
0.1 0.2 0.3 0.4 0.5 1.0 |
1 2 3 4 5 10 |
1.1 2.2 3.3 4.4 5.5 11 |
§
Before opening or reconstitution, all kits components are stable until
the expiry date, indicated on the vial label, if kept at 2 to 8°C.
§
Unused strips must be stored, at 2-8°C, in a sealed bag containing a
desiccant until expiration date.
§
After reconstitution, calibrators, controls and CT free serum should be
frozen immediately after use and kept at –20°C for 3 months.
Only one freeze thawing cycle is allowed, discard the calibrators,
controls and CT free serum after the second use.
§
The concentrated Wash Solution is stable at room temperature until
expiration date.
§
Freshly prepared Working Wash solution should be used on the same day.
§
After its first use, the concentrated conjugate (11x) is stable until
expiry date, if kept in the original well-closed vial at 2 to 8°C.
§
The Working anti-CT-HRP conjugate is stable for 1 week at 4°C.
§
The chromogenic TMB solution and the Stop Solution are stable at 2°C to
8°C until the expiry date.
§
Alterations in physical appearance of kit reagents may indicate
instability or deterioration.
8.
SPECIMEN
COLLECTION
AND
PREPARATION
§
Serum and plasma must be kept at 2 - 8°C.
§
If the test is not run within 24 hours, storage in aliquots at -20°C is
recommended. Avoid subsequent
freeze thaw cycles.
§
Prior to use, all samples should be at room temperature.
It is recommended to vortex the samples before use.
§
Serum or EDTA plasma provide similar results.
Y(serum)
= 0.84 x (EDTA plasma) – 2.4 pg/ml
r=0.90 n=15
§
Do not use haemolysed samples.
§
Do not use lipemic samples.
9
PROCEDURE
A.
Handling notes
Do not use the kit or components beyond expiry date.
Do
not mix materials from different kit lots.
Bring
all the reagents to room temperature prior to use.
Thoroughly mix all reagents and samples by gentle agitation or swirling.
Perform calibrators, controls and samples in duplicate. Vertical alignment is recommended.
Use a clean plastic container to prepare the Wash Solution.
In order to avoid cross-contamination, use a clean disposable pipette tip
for the addition of each reagent and sample.
For the dispensing of the Chromogenic Solution and the Stop Solution
avoid pipettes with metal parts.
High precision pipettes or automated pipetting equipment will improve the
precision.
Respect the incubation times.
Prepare a calibration
curve for each run, do not use data from previous runs.
The
chromogenic solution should be colourless.
If a dark blue colour develops within a few minutes after preparation,
this indicates that the preparation is unusable and must be discarded.
Dispense
the Chromogenic Solution within 15 minutes following the washing of the
microtiterplate.
During
incubation with Chromogenic Solution, avoid direct sunlight on the
microtiterplate.
B.
Procedure
1. Select the required number of strips for the run. The unused strips should be resealed in the bag with a desiccant and stored at 2-8°C.
2. Secure the strips into the holding frame.
3. Pipette 50 µl of each Calibrator, Control and Sample into the appropriate wells.
4. Pipette 100 µl of Working anti-CT-HRP conjugate into all the wells.
5. Incubate for 18 ± 1 hour at 2-8°C.
6. Aspirate the liquid from each well.
7. Wash the plate 4 times by:
§ dispensing 0.4 ml of Wash Solution into each well
§ aspirating the content of each well
8. Pipette 50 µl of the Chromogenic solution into each well within 15 minutes following the washing step.
9. Incubate the microtiterplate for 30 minutes at room temperature on a horizontal shaker set at 700 rpm ± 100 rpm, avoid direct sunlight.
10. Pipette 200 µl of Stop Solution into each well.
11. Read the absorbances at 450 nm and 490 nm (reference filter 630 nm or 650 nm) within 3 hours and calculate the results as described in section XI.
10.
CALCULATION
OF
RESULTS
A.
Polychromatic Reading:
1.
In this case, the ELISA-AID™ software will do the data processing.
2.
The plate is first read at 450 nm against a reference filter set at 650
nm (or 630 nm).
3.
A second reading is performed at 490 nm
against the same reference filter.
4.
The ELISA-AID™ Software will drive the reader automatically and will
integrate both readings into a polychromatic model.
This technique can generate OD’s up to 10.
5.
The principle of polychromatic data processing is as follows:
§
Xi = OD at 450 nm
§
Yi = OD at 490 nm
§
Using a standard unweighted linear regression, the parameters A & B
are calculated : Y = A*X – B
§
If Xi < 3 OD units, then X calculated = Xi
§
If Xi > 3 OD units, then X calculated = (Yi-B)/A
§
A 4-parameter logistic curve fitting is used to build up the calibration
curve.
§
The CT concentration in samples is determined by interpolation on the
calibration curve.
B.
Bichromatic Reading
1.
Read the plate at 450 nm against a reference filter set at 650 nm (or 630
nm).
2.
Calculate the mean of duplicate determinations.
3.
On semi-logarithmic or linear graph paper plot the OD values (ordinate)
for each calibrator against the corresponding concentration of Calcitonin
(abscissa) and draw a calibration curve through the calibrator points by
connecting the plotted points with straight lines.
4.
Read the concentration for each control and sample by interpolation on
the calibration curve.
5.
Computer assisted data reduction will simplify these calculations.
If automatic result processing is used, a 4-parameter logistic function
curve fitting is recommended.
11.
TYPICAL DATA
The
following data are for illustration only and should never be used instead of the
real time calibration curve.
|
CT-U.S.-ELISA |
Polychromatic
model (OD) |
Bichromatic
model (OD) |
|
|
Calibrator |
0
pg/ml 5
pg/ml 40
pg/ml 130
pg/ml 270
pg/ml 950
pg/ml
|
0.018 0.131 0.410 1.20 2.53 6.60 |
0.010 0.043 0.126 0.370 0.765 2.02 |
12.
PERFORMANCE
AND
LIMITATIONS
A.
Detection Limit
Twenty
zero calibrators were assayed along with a set of other calibrators. The
detection limit, defined as the apparent concentration two standard deviations
above the average OD at zero binding, was 0.5 pg/ml.
B. Specificity
Some
potentially interfering hormones have been tested in this assay.
At concentrations up to 100 ng/ml, none of the following hormones showed
significant interference :
-
CGRP
-
Salmon-calcitonin
-
PDN 21
-
Procalcitonin N terminal.
C.
Precision
|
INTRA
ASSAY |
INTER
ASSAY |
||||||
|
Serum |
N |
<
>
± SD (pg/ml) |
CV (%) |
Serum |
N |
<
>
± SD (pg/ml) |
CV (%) |
|
A B |
10 10 |
36.7
± 1.0 259.7
± 6.3 |
2.8 2.4 |
A B |
20 20 |
41.3
±
3.6 167.3
±
10.5 |
8.6 6.3 |
SD
: Standard Deviation; CV: Coefficient of variation
D.
Accuracy
RECOVERY
TEST
|
Added
CT (pg/ml) |
Recovered
CT (pg/ml) |
Recovery (%) |
|
475
135
65
20 |
414
124
63
20 |
87
92
97
100 |
|
DILUTION TEST |
|||
|
Sample |
Dilution |
Theoretical
Concent. (pg/ml) |
Measured
Concent. (pg/ml) |
|
Serum
1 |
1/1 1/2 1/4 1/8 1/16 1/32 1/64 1/128 |
- 312 156 78 39 20 9.8 4.9 |
624
325
158
84
42
21
9.1
4.1
|
Samples
were diluted with CT Free Serum.
E.
Hook effect
A
sample spiked with CT up to 830000 pg/ml gives
higher OD’s than the last calibrator point.
13
INTERNAL QUALITY
CONTROL
§
If the results obtained for Control 1 and/or Control 2 are not within the
range specified on the vial label, the results cannot be used unless a
satisfactory explanation for the discrepancy has been given.
§
If desirable, each laboratory can make its own pools of control samples,
which should be kept frozen in aliquots. Controls which contain azide will
interfere with the enzymatic reaction and cannot be used.
§
Acceptance criteria for the difference between the duplo results of the
samples should rely on Good Laboratory Practises
§
It is recommended that Controls be routinely assayed as unknown samples
to measure assay variability. The
performance of the assay should be monitored with quality control charts of the
controls.
§
It is good practise to check visually the curve fit selected by the
computer.
These values are given only for guidance; each laboratory should establish its own normal range of values.
Normal
values
20 samples from normal
subjects obtained values below 11 pg/ml.
Pentagastrin
test:
Patient
with MTC with elevated base levels of CT: to
verify
|
Time
after Pentagastrin Stimulation (min) |
CT
measured with CT-U.S.-ELISA (pg/ml) |
|
0
1
2
5
10
20 |
4800 8200 34400 29300 21900 14900 |
15.
PRECAUTIONS
AND
WARNINGS
Safety
For
in vitro diagnostic use only.
The
human blood components included in this kit have been tested by European
approved and/or FDA approved methods and found negative for HBsAg, anti-HCV,
anti-HIV-1 and 2. No known method
can offer complete assurance that human blood derivatives will not transmit
hepatitis, AIDS or other infections. Therefore,
handling of reagents, serum or plasma specimens should be in accordance with
local safety procedures.
All
animal products and derivatives have been collected from healthy animals. Bovine
components originate from countries where BSE has not been reported.
Nevertheless, components containing animal substances should be treated as
potentially infectious.
Avoid
any skin contact with all reagents, Stop
Solution contains HCl, the chromogenic solution contains TMB and H2O2.
In case of contact, wash thoroughly with water.
Do
not smoke, drink, eat or apply cosmetics in the working area.
Do not pipette by mouth. Use
protective clothing and disposable gloves.
16
BIBLIOGRAPHY
1.
GRAZE K., SPILER I.J., TASHIJAN A.H., MELVIN K.E.W., CERVI-SKINNER S.,
GAGEL R.F., MILLER H.H., WOLFE H.J., DELELLIS R.A., LEAPE L., FELDMAN Z.T. and
REICHLIN S. (1978)
Natural
history of familial medullary thyroid carcinoma; Effect of a program for early
diagnosis.
Engl.
J. Med., 299,18;980-985.
2.
HENNESSY J.F., WELLS S.A., ONTJES D.A. and COOPER C.W.
(1974)
A
comparison of pentagastrin injection and calcium infusion as provocative agents
for the detection of medullary carcinoma of the thyroid.
J.
Clin. Endocrinol. Metab., 39:487-495.
3.
ROUGIER Ph., CALMETTES C., LAPLANCHE A., TRAVAGLI J.P., LEFEVRE M.,
PARMENTIER C., MILHAUD G. and TUBIANA M. (1983)
the
values of calcitonin and carcinoembryonic antigen in the treatment and
management of nonfamilial medullary thyroid carcinoma.
Cancer, 51,5:856-862.
4.
WALLACH S.R., ROYSTON I., TAETLE
R., WOHL H. and DEFTOS
L. (1981)
Plasma
calcitonin as a marker of disease activity in patients with small cell carcinoma
of the lung.
J.
Clin. Endocrinol. Metab., 53,3:602-606.
5.
WELLS S.A., BAYLIN S.B., LINEHAN W.M., FARRELL R.E., COX E.B. and COOPER
C.W. (1978)
Provocative agents and the diagnosis of medullary carcinoma of the
thyroid gland.
Ann.
Surg., 188,2:139-141.
6.
AURBACH G.D., MARX S.J. and SPIEGEL A.M.
(1985)
Parathyroid
hormone, calcitonin, and the calciferols.
In:
williams Textbook of endocrinology (7th edition; Wilson J.D. and foster D.W.
eds) W.B. Saunders Company, Philadelphia, 1137-1217.
7.
BODY J.J. et al. (1987)
SCC
antigen and other tumor markers in lung cancer: preliminary results.
Excerpta
Medica, 162-170.
8.
NICOLI P. et al. (1995)
Abnormal
calcitonin basal levels and pentagastrin response in patients with chronic renal
failure on maintenance hemodialysis.
Eur.
J. Endocrinol. 132, 1, 75-81.
9.
PACINI F. et al. (1994)
Routine
measurement of serum calcitonin in modular disease allows the preoperative
diagnosis of unsuspected sporadic medullary thyroid carcinoma.
J.
Clin. Endocrinol. Metab. Excerpta Medica, 78, 4, 824-9.
10.
QUESADA J. M. et al. (1994)
Calcitriol
corrects deficient calcitonin secretion in the Vit. D deficient elderly.
J.
Bone Miner Res. 9, 1, 53-57.
17
SUMMARY OF THE PROTOCOL
|
|
CALIBRATORS (µl) |
SAMPLE(S) CONTROLS (µl) |
|
Calibrators
(0-5) Controls,
Samples Working
Anti-CT-HRP conjugate |
50 - |
- 50 |
|
Incubate
for 18 ± 1 hours at 2 – 8°C. Aspirate
the contents of each well. Wash
4 times with 400 µl of Wash Solution and aspirate. |
||
|
Chromogenic
TMB Solution |
50 |
50 |
|
Incubate
for 30 min at room temperature with continuous shaking at 700 rpm. |
||
|
Stop
Solution |
200 |
200 |
|
Read
on a microtiterplate reader and record the absorbance of each well at
450 nm (versus 630 or 650 nm) and 490 nm (versus 630 or 650 nm) |
||
|